Pelthos Therapeutics Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Pelthos Therapeutics Inc. (market cap ~$6.7M) agreed to merge with Castle Creek Biosciences Inc. via two-step transaction. Pelthos will issue Merger Partner Merger Shares (unspecified count) to Castle Creek shareholders; concurrent financing of $57.5M minimum (Series B Preferred or Common Stock) plus up to $8.5M Bridge Notes. Contingent consideration includes cash, shares, milestone payments, and PRV Interest per Article IX. Deal dated October 30, 2026; closing contingent on shareholder approvals and regulatory conditions.
Why this rating
Transformational M&A for micro-cap: ~$66M financing + acquisition of biotech platform material relative to $6.7M valuation. Substantial dilution, governance changes (2 new directors), complex contingent payouts. Business-changing trajectory shift.
Tradability signal
NO TRADE
No trade: positive news with only -3.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.60% over 4 hrs, n=18). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $17.51 | +10 min · unknown $14.26 ▼ 18.56% | +30 min · unknown $11.76 ▼ 32.84% | +1 hr · unknown $11.06 ▼ 36.84% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.